Last reviewed · How we verify
DA-5212-R
DA-5212-R is a small molecule that modulates dopamine and serotonin pathways to treat cognitive and neuropsychiatric symptoms.
DA-5212-R is a small molecule that modulates dopamine and serotonin pathways to treat cognitive and neuropsychiatric symptoms. Used for Cognitive impairment associated with Alzheimer's disease or other neurodegenerative conditions, Neuropsychiatric symptoms in cognitive disorders.
At a glance
| Generic name | DA-5212-R |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Dopamine D2/D3 partial agonist; serotonin 5-HT1A agonist |
| Target | Dopamine D2/D3 receptors; serotonin 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | Phase 3 |
Mechanism of action
DA-5212-R acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A receptor agonist, helping to restore neurotransmitter balance in the brain. This dual mechanism is designed to improve cognitive function and reduce neuropsychiatric symptoms associated with neurodegenerative diseases and cognitive disorders.
Approved indications
- Cognitive impairment associated with Alzheimer's disease or other neurodegenerative conditions
- Neuropsychiatric symptoms in cognitive disorders
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |